Fitt Insider Create Scores $20M, Eli Lilly Bets on AI Drugs, Landmark Social Media Verdict
Mar 31, 2026
A big pharma bet on AI drug discovery with a multi-billion dollar deal and reinvestment of GLP-1 profits into next‑gen pipelines. A landmark California verdict finds major platforms liable for youth harms tied to addictive product design like infinite scroll and autoplay. A wellness brand raises $20M after selling over 100M creatine gummies and expands into mainstream retail.
AI Snips
Chapters
Transcript
Episode notes
Pharma Reinvests GLP-1 Profits Into AI Drug Discovery
- Eli Lilly is turning GLP-1 windfalls into AI-powered R&D to build tomorrow's drug pipeline.
- Lilly signed a $2.75B Insilico deal with $115M upfront and a $1B NVIDIA co-innovation lab to make AI core to discovery.
Court Treats Social Platforms As Product Safety Problems
- The California verdict reframes digital harms as product safety rather than content issues.
- A jury found Meta and Google liable for youth harms tied to design features like infinite scroll and autoplay, awarding $6M.
Create Wellness Scales With Gummies Then Expands Formats
- Create Wellness sold over 100 million creatine gummies and grew 4x last year.
- The brand expanded distribution to major retailers and launched a powder combining creatine with electrolytes.